NCT04483284View on ClinicalTrials.gov

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

TACE combined with Camrelizumab

Camrelizumab(200mg q3w ivgtt) combined with TACE

PROCEDURE

TACE plus Camrelizumab

Camrelizumab(200mg q3w ivgtt) combined with TACE

Trial Locations (1)

200032

Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER